Skip to main content
Top
Published in: Neuroradiology 2/2010

01-02-2010 | Diagnostic Neuroradiology

Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves’ orbitopathy—a pilot study at 1.5 T

Authors: Eberhard C. Kirsch, Achim H. Kaim, Marion Gregorio De Oliveira, Georg von Arx

Published in: Neuroradiology | Issue 2/2010

Login to get access

Abstract

Introduction

This study seeks to describe the predictive value of the signal intensity ratio (SIR) in magnetic resonance imaging-turbo inversion recovery magnitude (MRI-TIRM) in patients with Graves’ orbitopathy (GO) with regard to predictability of therapy response.

Methods

Included in this prospective pilot study were 36 consecutive patients with GO and 25 control subjects. Patients were clinically assessed according to the European Group on Graves’ Orbitopathy recommendations with active GO defined by a clinical activity score (CAS) ≥ 3. On magnetic resonance (MR) imaging, muscle inflammation was measured with a region of interest set within the brightest extra-ocular muscle both on coronal turbo inversion recovery magnitude (TIRM) and on fat suppressed gadolinium-enhanced T1-weighted sequences. To calculate the SIR, the measured signal intensity was set in proportion to that of the ipsilateral temporalis muscle.

Results

Signal intensity ratio in coronal T2-weighted TIRM sequences in either group ranged from 1.22 to 4.92 (mean 2.04) in patients with GO and from 1.18 to 2.4 (mean 1.63) in controls without GO. The observed differences were significant on the TIRM sequences (right eye p = 0.023; left eye p = 0.022), whereas, no significant differences could be detected on the T1-weighted sequences (right eye p = 0.396; left eye p = 0.498). A cut off value of SIR > 2.5 for a CAS ≥ 4 to discriminate active from inactive patients was statistically calculated.

Conclusion

T2 relaxation time is a reliable tool in detecting active GO. The difference in T2-SIR versus T1-SIR is helpful to distinguish inflammatory oedema of the extra ocular muscles from intra-orbital congestion due to reduced venous outflow.
Literature
1.
go back to reference Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activityscore as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 47:9–14CrossRef Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activityscore as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 47:9–14CrossRef
2.
go back to reference Gerding MN, Prummel MF, Wiersinga WM (2000) Assessment of disease activity in Graves’ ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 52:641–646CrossRef Gerding MN, Prummel MF, Wiersinga WM (2000) Assessment of disease activity in Graves’ ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 52:641–646CrossRef
3.
go back to reference Young IR, Bydder GM, Hajnal JV (1997) Contrast properties of the inversion recovery sequence. In: Bradley WG Jr, Bydder GM (eds) Advanced MR Imaging Techniques. Martin Dunitz Ltd, London, pp 143–162 Young IR, Bydder GM, Hajnal JV (1997) Contrast properties of the inversion recovery sequence. In: Bradley WG Jr, Bydder GM (eds) Advanced MR Imaging Techniques. Martin Dunitz Ltd, London, pp 143–162
4.
go back to reference European Group on Graves’ Orbitopathy (EUGOGO), Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G (2006) Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155:387–389CrossRefPubMed European Group on Graves’ Orbitopathy (EUGOGO), Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G (2006) Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155:387–389CrossRefPubMed
5.
go back to reference Chang E, Wilson MW, Smith ME (2002) Orbital Imaging in Thyroid Eye Disease.In: Dutton JJ, Haik BG.Thyroid Eye Disease. Diagnosis and Treatment 30:301–308 Chang E, Wilson MW, Smith ME (2002) Orbital Imaging in Thyroid Eye Disease.In: Dutton JJ, Haik BG.Thyroid Eye Disease. Diagnosis and Treatment 30:301–308
6.
go back to reference Bartalena L, Wiersinga WM, Pinchera A (2004) Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 27:295–301PubMed Bartalena L, Wiersinga WM, Pinchera A (2004) Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 27:295–301PubMed
7.
go back to reference Salvi M, Dazzi D, Pellistri I, Neri F, Wall JR (2002) Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network. Ophthalmology 109:1703–1708CrossRefPubMed Salvi M, Dazzi D, Pellistri I, Neri F, Wall JR (2002) Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network. Ophthalmology 109:1703–1708CrossRefPubMed
8.
go back to reference Eckstein A, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470CrossRefPubMed Eckstein A, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470CrossRefPubMed
9.
go back to reference Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, Mann K, Esser J, Morgenthaler NG (2007) Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 67:607–612 Eckstein AK, Lax H, Lösch C, Glowacka D, Plicht M, Mann K, Esser J, Morgenthaler NG (2007) Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 67:607–612
10.
go back to reference Noth D, Gebauer M, Müller B, Bürgi U, Diem P (2001) Graves’ ophthalmopathy: natural history and treatment outcomes. Swiss Med Wkly 131:603–609PubMed Noth D, Gebauer M, Müller B, Bürgi U, Diem P (2001) Graves’ ophthalmopathy: natural history and treatment outcomes. Swiss Med Wkly 131:603–609PubMed
11.
go back to reference Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A (2000) Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 10:891–896CrossRefPubMed Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A (2000) Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 10:891–896CrossRefPubMed
12.
go back to reference Villadolid MC, Yokoyama N, Izumi M, Nishikawa T, Kimura H, Ashizawa K, Kiriyama T, Uetani M, Nagataki S (1995) Untreated Graves’ disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 80:2830–2833CrossRefPubMed Villadolid MC, Yokoyama N, Izumi M, Nishikawa T, Kimura H, Ashizawa K, Kiriyama T, Uetani M, Nagataki S (1995) Untreated Graves’ disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 80:2830–2833CrossRefPubMed
13.
go back to reference Ohnishi T, Noguchi S, Murakami N, Tajiri J, Harao M, Kawamoto H, Hoshi H, Jinnouchi S, Futami S, Nagamachi S (1994) Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements. Radiology 190:857–862PubMed Ohnishi T, Noguchi S, Murakami N, Tajiri J, Harao M, Kawamoto H, Hoshi H, Jinnouchi S, Futami S, Nagamachi S (1994) Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements. Radiology 190:857–862PubMed
14.
go back to reference Pauleit D, Schüller H, Textor J, Leutner C, Keller E, Sommer T, Träber F, Block W, Boldt I, Schild H (1997) MR relaxation time measurements with and without selective fat suppression (SPIR) in endocrine orbitopathy. ROFO 167:557–564PubMed Pauleit D, Schüller H, Textor J, Leutner C, Keller E, Sommer T, Träber F, Block W, Boldt I, Schild H (1997) MR relaxation time measurements with and without selective fat suppression (SPIR) in endocrine orbitopathy. ROFO 167:557–564PubMed
15.
go back to reference Laitt RD, Hoh B, Wakely C, Kabala J, Harrad R, Potts M (1994) The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Br J Radiol 67:244–247CrossRefPubMed Laitt RD, Hoh B, Wakely C, Kabala J, Harrad R, Potts M (1994) The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Br J Radiol 67:244–247CrossRefPubMed
16.
go back to reference Amano Y, Amano M, Kumazaki T (1997) Normal contrast enhancement of extraocular muscles: fat-suppressed MR findings. Am J Neuroradiol 18:161–164PubMed Amano Y, Amano M, Kumazaki T (1997) Normal contrast enhancement of extraocular muscles: fat-suppressed MR findings. Am J Neuroradiol 18:161–164PubMed
17.
go back to reference Link TM, Reimer P, Rummeny EJ, Schuierer G, Grenzebach U, Peters PE (1995) The MRT of the orbit: the value of T1-weighted frequency-selective fat saturation at 1.0 and 1.5 tesla. ROFO 163:406–410PubMed Link TM, Reimer P, Rummeny EJ, Schuierer G, Grenzebach U, Peters PE (1995) The MRT of the orbit: the value of T1-weighted frequency-selective fat saturation at 1.0 and 1.5 tesla. ROFO 163:406–410PubMed
18.
go back to reference Cakirer S, Cakirer D, Basak M, Durmaz S, Altuntas Y, Yigit U (2004) Evaluation of extraocular muscles in the edematous phase of Graves ophthalmopathy on contrast-enhanced fat-suppressed magnetic resonance imaging. J Comput Assist Tomogr 28:80–86CrossRefPubMed Cakirer S, Cakirer D, Basak M, Durmaz S, Altuntas Y, Yigit U (2004) Evaluation of extraocular muscles in the edematous phase of Graves ophthalmopathy on contrast-enhanced fat-suppressed magnetic resonance imaging. J Comput Assist Tomogr 28:80–86CrossRefPubMed
19.
go back to reference Yanik B, Conkbayir I, Acaroglu G, Hekimoglu B (2005) Graves’ ophthalmopathy: comparison of the Doppler sonography parameters with the clinical activity score. J Clin Ultrasound 33:375–380CrossRefPubMed Yanik B, Conkbayir I, Acaroglu G, Hekimoglu B (2005) Graves’ ophthalmopathy: comparison of the Doppler sonography parameters with the clinical activity score. J Clin Ultrasound 33:375–380CrossRefPubMed
20.
go back to reference Alp MN, Ozgen A, Can I, Cakar P, Gunalp I (2000) Colour Doppler imaging of the orbital vasculature in Graves’ disease with computed tomographic correlation. Br J Ophthalmol 84:1027–1030CrossRefPubMed Alp MN, Ozgen A, Can I, Cakar P, Gunalp I (2000) Colour Doppler imaging of the orbital vasculature in Graves’ disease with computed tomographic correlation. Br J Ophthalmol 84:1027–1030CrossRefPubMed
21.
go back to reference Ott M, Breiter N, Albrecht CF, Pradier O, Hess CF, Schmidberger H (2002) Can contrast enhanced MRI predict the response of Graves’ ophthalmopathy to orbital radiotherapy? Br J Radiol 75:514–517PubMed Ott M, Breiter N, Albrecht CF, Pradier O, Hess CF, Schmidberger H (2002) Can contrast enhanced MRI predict the response of Graves’ ophthalmopathy to orbital radiotherapy? Br J Radiol 75:514–517PubMed
22.
go back to reference Taoka T, Sakamoto M, Nakagawa H, Fukusumi A, Iwasaki S, Taoka K, Kichikawa K (2005) Evaluation of extraocular muscles using dynamic contrast enhanced MRI in patients with chronic thyroid orbitopathy. J Comput Assist Tomogr 29:115–120CrossRefPubMed Taoka T, Sakamoto M, Nakagawa H, Fukusumi A, Iwasaki S, Taoka K, Kichikawa K (2005) Evaluation of extraocular muscles using dynamic contrast enhanced MRI in patients with chronic thyroid orbitopathy. J Comput Assist Tomogr 29:115–120CrossRefPubMed
23.
go back to reference Mayer EJ, Fox DL, Herdmann G, Hsuan J, Kabala J, Goddard P, Potts MJ, Lee RWJ (2005) Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol 56:20–24CrossRefPubMed Mayer EJ, Fox DL, Herdmann G, Hsuan J, Kabala J, Goddard P, Potts MJ, Lee RWJ (2005) Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol 56:20–24CrossRefPubMed
Metadata
Title
Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves’ orbitopathy—a pilot study at 1.5 T
Authors
Eberhard C. Kirsch
Achim H. Kaim
Marion Gregorio De Oliveira
Georg von Arx
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Neuroradiology / Issue 2/2010
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI
https://doi.org/10.1007/s00234-009-0590-z

Other articles of this Issue 2/2010

Neuroradiology 2/2010 Go to the issue